bifeprunoxum
Small moleculeexperimental
Clinical trial activity
19 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
18
Phase 3
14
Phase 4
0
Earliest trial started Feb 1, 2005 (NCT00141505)
Timeline
Indications
Mechanism of action
- Dopamine D2 receptorPARTIAL AGONIST
DRD2 partial agonist
High affinity: D3 and D4 receptors. Low affinity: a1, 5HT2A, 5HT2C, H1 and muscarinic receptors
- Serotonin 1a (5-HT1a) receptorPARTIAL AGONIST
HTR1A partial agonist
High affinity: D3 and D4 receptors. Low affinity: a1, 5HT2A, 5HT2C, H1 and muscarinic receptors
Chemistry & pharmacology
Loading structure…
SMILES
O=c1[nH]c2cccc(N3CCN(Cc4cccc(-c5ccccc5)c4)CC3)c2o1- Mol. weight
- 385.47 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL218166 ↗
Also known as
- 1-(2-oxo-benzoxazolin-7-yl)-4-(3-biphenyl)methylpiperazinemesylate
- bifeprunox
- bifeprunox
- bifeprunox
- bifeprunox
- bifeprunox
- bifeprunox mesilate
- bifeprunox mesilate
- bifeprunox mesilate
- bifeprunoxum
- bifeprunoxum
- du127090
- du-127090
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00704509 | Phase 3 | Jun 1, 2008 | Lundbeck |
| NCT00658645 | Phase 3 | Mar 1, 2008 | Lundbeck |
| NCT00581451 | Phase 1 | Oct 1, 2007 | Pfizer, Wyeth |
| NCT00396214 | Phase 3 | Apr 1, 2007 | Lundbeck, Solvay, Wyeth |
| NCT00366327 | Phase 3 | Jan 1, 2007 | Pfizer, Wyeth |
| NCT00366171 | Phase 3 | Nov 1, 2006 | Pfizer, Wyeth |
| NCT00366704 | Phase 3 | Nov 1, 2006 | Pfizer, Solvay, Wyeth |
| NCT00380224 | Phase 3 | Jul 1, 2006 | Pfizer, Wyeth |
| NCT00861497 | Phase 3 | Jan 1, 2006 | Lundbeck, Solvay |
| NCT00139919 | Phase 2 | Jan 1, 2006 | Lundbeck, Solvay, Wyeth |
| NCT00160147 | Phase 3 | Dec 1, 2005 | Solvay |
| NCT00193687 | Phase 3 | Sep 1, 2005 | Solvay |
| NCT00139906 | Phase 2 | Aug 1, 2005 | Lundbeck, Solvay, Wyeth |
| NCT00245973 | Phase 3 | Jun 1, 2005 | Pfizer, Solvay, Wyeth |
| NCT00134459 | Phase 3 | Jun 1, 2005 | Pfizer, Solvay, Wyeth |
| NCT00230828 | Phase 3 | May 1, 2005 | Solvay |
| NCT00193713 | Phase 3 | May 1, 2005 | Solvay |
| NCT00141479 | Phase 2 | May 1, 2005 | Lundbeck, Solvay, Wyeth |
| NCT00141505 | Phase 2 | Feb 1, 2005 | Lundbeck, Solvay, Wyeth |
Showing 19 of 19 trials
Page 1 / 1